Limits...
A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice.

Liu X, Qiang W, Liu X, Liu L, Liu S, Gao A, Gao S, Shi B - Eur. J. Endocrinol. (2014)

Bottom Line: Group 2 was continuously reduced to 2.5 mg every other day (qod) after 5 months and then discontinued with 2.5 mg qod after about a further 5 months.The patients were followed for 48 months after drug withdrawal.Cox regression showed that the hazard ratio for recurrence decreased under a high or high normal TSH level at drug withdrawal.

View Article: PubMed Central - PubMed

Affiliation: Department of EndocrinologyFirst Affiliated Hospital of Xi'an Jiaotong University, No. 277 Yanta West Road, Xi'an, Shaanxi 710061, China.

Show MeSH

Related in: MedlinePlus

The remission plots of patients (%) remaining euthyroid after drug withdrawal in two groups with different discontinuation drug doses (Kaplan–Meier survival analysis). Log rank test shows P=0.024.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4321192&req=5

fig1: The remission plots of patients (%) remaining euthyroid after drug withdrawal in two groups with different discontinuation drug doses (Kaplan–Meier survival analysis). Log rank test shows P=0.024.

Mentions: The number of cumulative recurrence during the follow-up is given in Table 2. Out of 128, 31 (24.22%) patients had a relapse during the 48 months after MMI withdrawal. Relapse was found in 21 out of 63 (33.33%) in group 1 and ten out of 65 (15.38%) in group 2. In total, 97 out of 128 (75.78%) patients achieved permanent remission at the end of the follow-up. Figure 1 shows that the remission rate of group 2 was significantly higher than that of group 1 (P=0.024, Kaplan–Meier survival analysis).


A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice.

Liu X, Qiang W, Liu X, Liu L, Liu S, Gao A, Gao S, Shi B - Eur. J. Endocrinol. (2014)

The remission plots of patients (%) remaining euthyroid after drug withdrawal in two groups with different discontinuation drug doses (Kaplan–Meier survival analysis). Log rank test shows P=0.024.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4321192&req=5

fig1: The remission plots of patients (%) remaining euthyroid after drug withdrawal in two groups with different discontinuation drug doses (Kaplan–Meier survival analysis). Log rank test shows P=0.024.
Mentions: The number of cumulative recurrence during the follow-up is given in Table 2. Out of 128, 31 (24.22%) patients had a relapse during the 48 months after MMI withdrawal. Relapse was found in 21 out of 63 (33.33%) in group 1 and ten out of 65 (15.38%) in group 2. In total, 97 out of 128 (75.78%) patients achieved permanent remission at the end of the follow-up. Figure 1 shows that the remission rate of group 2 was significantly higher than that of group 1 (P=0.024, Kaplan–Meier survival analysis).

Bottom Line: Group 2 was continuously reduced to 2.5 mg every other day (qod) after 5 months and then discontinued with 2.5 mg qod after about a further 5 months.The patients were followed for 48 months after drug withdrawal.Cox regression showed that the hazard ratio for recurrence decreased under a high or high normal TSH level at drug withdrawal.

View Article: PubMed Central - PubMed

Affiliation: Department of EndocrinologyFirst Affiliated Hospital of Xi'an Jiaotong University, No. 277 Yanta West Road, Xi'an, Shaanxi 710061, China.

Show MeSH
Related in: MedlinePlus